The information you are about to see is intended for U.S. healthcare professionals.
Please confirm you are a U.S. healthcare professional.
I am a licensed U.S. healthcare professional
I am NOT a licensed U.S. healthcare professional
You are leaving this website
You are now leaving Galafoldhcp.com. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.
Exit the request a representative window

Request more information or a visit from your Amicus Rare Disease Specialist

Find out if Galafold® (migalastat) may be an appropriate treatment for your adult patients with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant. Once you submit your request, a representative will contact you.

Please fill in all fields below and submit your request.

*Required Fields.
Which of the following would you like more information on? (Check all that apply.)
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Exit the request a representative window
Thank you for your request!
INDICATIONS AND USAGE

Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Open or close the important safety information

Goes Where Your Patients Go

Galafold is a 123 mg capsule
Find out what Galafold can offer as an oral option for your adult patients with Fabry disease and an amenable GLA variant
Rebecca and her son Anthony, living with Fabry disease

An oral option for adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant associated with either the classic* or non-classic phenotype.1,2

*

Defined as males with residual peripheral blood mononuclear cell alpha-galactosidase A (alpha-Gal A) <3% of normal and multiorgan system involvement.2

Start a Patient

Start a Patient

The Galafold Patient Referral Form serves both as a prescription for Galafold in some states and a referral to AMICUS ASSIST®.

Download the form

Help your patients get support
with AMICUS ASSIST

AMICUS ASSIST is a program designed to provide education, assistance, and support in gaining access to Galafold to eligible patients with Fabry disease and an amenable GLA variant.
Visit
Patients must be prescribed Galafold to enroll in AMICUS ASSIST.

Check if your patient’s GLA variant
is amenable to Galafold

Use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information.
Check Now
Patients must be prescribed Galafold to enroll in AMICUS ASSIST.